- Home
- LPRO vs DRTS Comparison
LPRO vs DRTS Comparison
Compare LPRO & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- DRTS
- Stock Information
- Founded
- LPRO 2000
- DRTS 2015
- Country
- LPRO United States
- DRTS Israel
- Employees
- LPRO N/A
- DRTS N/A
- Industry
- LPRO Finance: Consumer Services
- DRTS Medical/Dental Instruments
- Sector
- LPRO Finance
- DRTS Health Care
- Exchange
- LPRO Nasdaq
- DRTS Nasdaq
- Market Cap
- LPRO 252.9M
- DRTS 300.2M
- IPO Year
- LPRO N/A
- DRTS N/A
- Fundamental
- Price
- LPRO $2.26
- DRTS $3.80
- Analyst Decision
- LPRO Buy
- DRTS Strong Buy
- Analyst Count
- LPRO 6
- DRTS 1
- Target Price
- LPRO $3.00
- DRTS $9.00
- AVG Volume (30 Days)
- LPRO 557.8K
- DRTS 64.8K
- Earning Date
- LPRO 11-06-2025
- DRTS 11-18-2025
- Dividend Yield
- LPRO N/A
- DRTS N/A
- EPS Growth
- LPRO N/A
- DRTS N/A
- EPS
- LPRO N/A
- DRTS N/A
- Revenue
- LPRO $16,254,999.00
- DRTS N/A
- Revenue This Year
- LPRO $311.24
- DRTS N/A
- Revenue Next Year
- LPRO $13.17
- DRTS N/A
- P/E Ratio
- LPRO N/A
- DRTS N/A
- Revenue Growth
- LPRO N/A
- DRTS N/A
- 52 Week Low
- LPRO $0.70
- DRTS $2.11
- 52 Week High
- LPRO $6.92
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- LPRO 55.11
- DRTS 63.54
- Support Level
- LPRO $2.06
- DRTS $3.51
- Resistance Level
- LPRO $2.34
- DRTS $3.94
- Average True Range (ATR)
- LPRO 0.13
- DRTS 0.18
- MACD
- LPRO 0.01
- DRTS 0.01
- Stochastic Oscillator
- LPRO 75.76
- DRTS 76.54
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.